Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer

A recent study, published in Clinical Genitourinary Cancer reports a meta-analysis comparing the tolerability and efficacy of a 2 weeks on treatment/1 week off treatment sunitinib dosing schedule with the traditional 4/2 schedule in patients with metastatic renal cell carcinoma (mRCC). Data from 1173 patients were included in the meta-analysis. The study showed that progression-free […]

read more

Low PD-L1 associated with long term response to sunitinib

Researchers from France have conducted a study to show that metastatic clear cell renal cell carcinoma (RCC) patients who have low expression of PD-L1 also have a long term response to sunitinib. However, low PD-L1 levels suggest a potentially lower impact of immunotherapy in these patients. Read more in Clinical Genitourinary Cancer here

read more

SMC approves nivolumab plus ipilimumab combination for advanced RCC

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of nivolumab plus ipilimumab for intermediate-/poor-risk advanced renal cell carcinoma (RCC) by NHS Scotland. The nivolumab (Opdivo) plus ipilimumab (Yervoy) combination was accepted following consideration through the SMC’s Patient and […]

read more

ASCO 2019: Biomarkers for advanced renal cell carcinoma from the JAVELIN Renal 101 study

Results from the biomarker analysis from the JAVALIN Renal 101 clinical trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago this week. JAVELIN Renal 101 compared the avelumab plus axitinib combination with sunitinib. There were 886 patients in the study, 442 received the combination and 444 received sunitinib. For […]

read more

Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

Results from this phase III trial of atezolizumab plus bevacizumab versus sunitinib for patients with untreated renal cell carcinoma (IMmotion 151) were published in The Lancet last month. The study involved 915 patients, of which 40% were positive for PD-L1 biomarkers. In the PD-L1 positive group of patients, the combination of atezolizumab plus bevacizumab was […]

read more

A review of adjuvant therapy options for kidney cancer

In this paper, published in Current Treatment Options in Oncology last month, the authors review the recent randomised controlled clinical trials looking at the use of post-surgery (adjuvant) vascular endothelial growth factor (VEGF) inhibitors for the treatment of renal cell carcinoma (RCC) that has not spread. The authors recommend, based on current data, that adjuvant […]

read more

Predictive biomarkers in metastatic kidney cancer

A review published in European Urology Focus looks at tools to optimise the choice and sequence of treatments to ensure the best clinical benefit for their metastatic renal cell carcinoma (RCC) patients. The review concludes that the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model is currently the only validated tool that can […]

read more

Targeted therapies with immunotherapies in kidney cancer

The following video is an interview with Professor Thomas Powles from Barts Cancer Centre in London, where he is Professor of Genitourinary Oncology. During the interview, Professor Powles discusses the results of the phase III KEYNOTE-426 trial presented at the 2019 Genitourinary Cancers Symposium.  The data from KETNOTE-426 potentially redefines the standard of care in […]

read more

Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer

The Food and Drug Administration (FDA) in the United States has approved the pembrolizumab (Keytruda) plus axitinib (Inlyta) combination for first-line treatment of advanced renal cell carcinoma (RCC). The approval comes two months earlier than expected and is based on the results from the open-label KEYNOTE-426 study involving 861 patients. In this study, median progression-free […]

read more

The hunt for a kidney cancer biomarker reveals two more potential candidates

As the hunt for a reliable biomarker for renal cell carcinoma (RCC) continues, two further studies this month reveal potential candidates. The first study, published in Targeted Oncology, describes serum (blood) α1-globulin as an independent predictor (prognostic factor) of overall survival and progression-free survival in metastatic RCC, and is correlated with a high amount of […]

read more
Showing 1 to 10 of 90 results
  TOP